TPO and TgAb Antibodies Explained

🦋 Interactive Visualization How Your Thyroid Is Controlled — run the feedback loop Watch thyroid-stimulating hormone (TSH) drive the thyroid, T4 convert to T3, and the loop feed back — then switch on Hashimoto's, Graves', or iodine deficiency. Launch →

What TPO Is and What Anti-TPO Antibodies Mean
What Thyroglobulin Is and What TgAb Means
How They're Measured and Reference Ranges
Prevalence in the General Population
Positive Antibodies with a Normal Thyroid-Stimulating Hormone
Severity, Titers, and Trajectory Over Time
Other Conditions with Positive TPO
How Far Antibody Levels Can Be Lowered
What Doesn't Reliably Lower Antibodies
When Antibodies Are Retested
Why Zero Isn't Always Possible or Necessary
TgAb's Special Role in Thyroid Cancer Monitoring
Antibody-Negative Hashimoto's
What Commonly Follows a Positive Result
Key Research Papers
Connections
Featured Videos

What TPO Is and What Anti-TPO Antibodies Mean

Thyroid peroxidase (TPO) is an enzyme anchored to the inner surface of the thyroid follicle cell. Its job is to take the iodide your thyroid has absorbed from the bloodstream, oxidize it, and stitch it onto a large protein scaffold called thyroglobulin. That iodination step is how your thyroid actually manufactures the hormones T4 and T3. Without TPO, no hormone gets made.

Because TPO sits at the hinge of hormone production, the immune system pays close attention to it. In Hashimoto's thyroiditis, B cells start producing antibodies that recognize TPO as if it were a foreign invader. These anti-TPO antibodies (often written "TPOAb" or "anti-TPOab") are a marker of autoimmune damage. They are not just a passive flag — they can fix complement and help recruit cytotoxic T cells to destroy thyroid follicles over years and decades.

A positive TPO antibody test tells you three things at once: your immune system has targeted the thyroid, the gland is being gradually attacked, and you are at elevated risk of eventual hypothyroidism. It does not, by itself, tell you whether your thyroid hormone levels are currently normal, low, or high. That requires a separate thyroid-stimulating hormone and free T4 measurement.

What Thyroglobulin Is and What TgAb Means

Thyroglobulin (Tg) is the massive storage protein — about 660,000 daltons — that fills the colloid inside each thyroid follicle. Think of it as the warehouse where newly made thyroid hormone is kept until the body calls for it. TPO iodinates specific tyrosine residues on thyroglobulin, and the resulting iodinated residues are later cleaved and released as T4 and T3.

Anti-thyroglobulin antibodies (TgAb or anti-Tg) target this warehouse protein. They are the second classical Hashimoto's antibody and are present in roughly 60–80% of Hashimoto's patients, often alongside TPO antibodies. A minority of patients (around 5–10%) are TgAb-positive but TPO-negative.

TgAb is generally considered a less specific marker than TPO. It is more common in healthy people without thyroid disease, and its titer tracks less cleanly with disease severity. But it matters for two reasons: it adds diagnostic confidence when TPO is borderline, and — critically — it interferes with thyroglobulin blood testing used to monitor thyroid cancer after surgery. More on that later.

How They're Measured and Reference Ranges

Both antibodies are measured on a simple blood draw using immunoassay platforms (most commonly chemiluminescent immunoassays on analyzers from different laboratory analyzer makers). Each platform reports in international units per milliliter (IU/mL), but the assays are not standardized to each other. A TPO of 120 international units/mL on one lab's platform may correspond to a different number on another lab's platform. This matters when labs change between tests — a result is read against the reference range printed on its own report, not against an old number from a different lab.

Typical upper limits of normal:

TPO antibodies: usually <9 international units/mL, though some labs cut off at <35 or <60 international units/mL depending on the assay.
TgAb: usually <1 international units/mL, though cutoffs of <4 or <20 international units/mL are also common.

Values are often reported as ranges: "low positive" (mildly above cutoff), "positive" (clearly elevated), and "strongly positive" (hundreds to thousands of international units/mL). Titers in the thousands are common in established Hashimoto's and are not, by themselves, worse than titers of a few hundred — both predict the same autoimmune process. A cost of $40–$120 per antibody test is typical in the U.S., and most insurers cover them when ordered with a thyroid-stimulating hormone as part of a thyroid workup.

Prevalence in the General Population

Thyroid autoantibodies are startlingly common in healthy-looking people. The NHANES III population study found that among 16,533 Americans aged 12 and over who did not report thyroid disease, TPO antibodies were positive in about 11% and TgAb in about 10%. Roughly 10% of adults have low-positive TPO titers and never develop clinical thyroid disease in their lifetime.

Several patterns are consistent across large cohorts:

Women are roughly three times more likely than men to be TPO-positive. Prevalence climbs from about 5% in young adult women to 20%+ in women over 60.
Prevalence rises with age in both sexes, reflecting the general drift of the aging immune system toward autoreactivity.
Ethnicity matters. In NHANES III, TPO positivity was about 12% in white and 4.5% in Black participants, and antibodies overall were more common in white and Mexican American participants than in Black participants.
Iodine-replete areas (including the U.S.) have higher antibody prevalence than mildly iodine-deficient regions — one of several observations linking iodine load to Hashimoto triggering.

The practical meaning: finding a positive TPO does not diagnose disease. It places you in a large, mostly healthy group that needs monitoring, not alarm.

Positive Antibodies with a Normal Thyroid-Stimulating Hormone

This is the most common real-world scenario: thyroid-stimulating hormone in range, free T4 normal, TPO positive. Labs sometimes call this "euthyroid autoimmune thyroiditis" or euthyroid Hashimoto's. The gland is under attack but still compensating.

The data on what happens next are consistent across decades of follow-up:

Roughly 3–5% per year of TPO-positive, euthyroid patients progress to overt hypothyroidism.
Another fraction first passes through subclinical hypothyroidism (thyroid-stimulating hormone elevated, free T4 still normal) before symptoms become unmistakable.
The higher the thyroid-stimulating hormone at baseline (even within the "normal" range, say above 2.5 mIU/L), and the higher the TPO titer, the faster progression tends to be.
A small minority of patients regress — antibodies fall, thyroid-stimulating hormone stabilizes, and they never develop clinical disease.

For this group, the usual approach is annual thyroid-stimulating hormone and free T4 monitoring, awareness of symptoms (fatigue, cold intolerance, weight gain, brain fog, hair thinning), and, for some people, the lifestyle interventions discussed below. Antibody positivity alone is not treated with thyroid hormone in standard care.

Severity, Titers, and Trajectory Over Time

Patients often ask whether a TPO of 900 is "worse" than a TPO of 200. The short answer: sort of, but not as much as you might expect.

At the population level, higher titers correlate with faster progression to hypothyroidism, more ultrasound heterogeneity (the classic hypoechoic, patchy Hashimoto's pattern), and a higher chance of needing levothyroxine within a given follow-up window. At the individual level, the signal is noisy. Many people with titers of 2,000+ international units/mL stay euthyroid for years. Many with titers of 60 international units/mL progress within 18 months.

Titers also fluctuate, sometimes dramatically, over years. A drop from 1,200 to 400 is not proof that an intervention worked — it may be natural variability, assay drift, or a change in the autoimmune activity of the moment. A single-timepoint change is not definitive. Trends over multiple measurements on the same assay tell you more.

Other Conditions with Positive TPO

Hashimoto's is the headline association, but TPO antibodies appear in a broader cluster of conditions:

Graves' disease — roughly 50% of Graves' patients have positive TPO, even though the driver of hyperthyroidism is a different antibody (thyroid-stimulating hormone receptor antibody, TRAb). TPO positivity in Graves' predicts a higher risk of eventually swinging into hypothyroidism after treatment.
Postpartum thyroiditis — up to 50% of women who are TPO-positive in pregnancy develop a transient thyroiditis in the first year after delivery, often biphasic (hyperthyroid then hypothyroid).
Type 1 diabetes — around 20–25% of type 1 diabetics carry TPO, reflecting polyglandular autoimmunity.
Celiac disease — significantly elevated TPO positivity; celiac patients also have higher Hashimoto's risk.
Other autoimmune conditions — rheumatoid arthritis, Sjögren's, lupus, pernicious anemia, Addison's disease, vitiligo, and autoimmune hepatitis all cluster with positive TPO above general-population rates.
Unexplained infertility and recurrent miscarriage — TPO positivity is associated with higher miscarriage risk even in euthyroid women, which is why many reproductive endocrinologists screen for it.

How Far Antibody Levels Can Be Lowered

Modestly, for some people, with specific interventions. No intervention reliably drives antibodies to zero. Here is the evidence, in rough order of strength:

Selenium 200 mcg/day

The best-studied supplement for Hashimoto's. In the landmark Gärtner 2002 randomized controlled trial (RCT) of 70 women with autoimmune thyroiditis, 200 mcg/day of selenium (as selenite) for 3 months lowered mean TPO antibodies to 63.6% of baseline (a fall of about 36%) versus 88% with placebo; the fall was about 40% in the subgroup with TPO above 1,200 IU/mL, and 9 selenium patients versus 2 placebo patients normalized. Multiple follow-up trials and the Toulis meta-analysis confirmed a real but modest effect: titers typically fall 20–40% over 3–6 months in responders. Selenium does not change thyroid-stimulating hormone or cure disease, and benefits plateau or reverse if you stop. Selenomethionine and selenite both work; selenomethionine is better tolerated. The adult tolerable upper intake level is 400 mcg/day — chronic high-dose selenium increases type 2 diabetes risk and can cause selenosis (hair loss, brittle nails, garlic breath).

Gluten-free diet

The Krysiak 2019 pilot study of 34 women with Hashimoto's and incidentally found positive tissue transglutaminase antibodies (16 on a gluten-free diet for 6 months, 18 without dietary change) found that the diet reduced thyroid antibody titers and slightly raised 25-hydroxyvitamin D. Observational cohorts show similar patterns, and Hashimoto's patients with undiagnosed celiac frequently see larger drops. The diet in that study was followed for 6 months; a "mostly gluten-free" diet is not what it tested.

Myo-inositol plus selenium

Small Italian studies (Nordio, Pace, others) using myo-inositol 600 mg + selenium 83 mcg twice daily have reported TPO reductions and thyroid-stimulating hormone improvements in subclinical hypothyroid Hashimoto's. Sample sizes are small and industry-sponsored, but the combination is safe and inexpensive.

Vitamin D correction

Observational data link low 25-hydroxyvitamin D to higher TPO titers. Correcting deficiency is associated with modest TPO reductions in several small trials; in one study from Crete, 186 vitamin D–deficient patients given vitamin D3 1,200–4,000 IU daily for 4 months (aiming for at least 40 ng/mL) had a 20.3% fall in anti-TPO. The effect size is smaller than selenium or gluten-free, but the intervention is cheap, safe, and has many independent health benefits.

Low-dose naltrexone

Low dose naltrexone (LDN) at 1.5–4.5 mg nightly has a growing anecdotal following in autoimmune disease, including Hashimoto's. Patient-reported symptom improvement is common; antibody data are limited to case series and small retrospective cohorts. It is a prescription drug, used off-label for this purpose.

Statins

Observational studies and a few small trials report that statin therapy lowers TPO titers, possibly via anti-inflammatory/immunomodulatory effects. Nobody prescribes statins for Hashimoto's alone, but in people already taking one for cardiovascular reasons this may show up as an incidental effect.

What Doesn't Reliably Lower Antibodies

Iodine supplementation. In established Hashimoto's, extra iodine (kelp, high-dose supplements, iodine-rich "thyroid support" blends) often raises antibodies and can precipitate hypothyroidism. The Recommended Dietary Allowance (RDA) is 150 mcg/day for adults and 220 mcg in pregnancy, an amount met by diet or a standard prenatal; high-dose iodine protocols run far above it.
Generic "anti-inflammatory" eating without a specific elimination. Swapping soda for green smoothies while still eating gluten produces little measurable antibody change.
Most supplement stacks — turmeric, ashwagandha, reishi, N-acetylcysteine (NAC) — have no controlled evidence of lowering TPO. Some may help symptoms; none reliably moves the antibody number.
Levothyroxine in euthyroid patients. Starting thyroid hormone when thyroid-stimulating hormone is normal does not lower antibodies and is not standard of care.

When Antibodies Are Retested

Less often than many people expect. Once the diagnosis is confirmed, antibody retesting has limited value in routine care because the number does not change management of hormone levels. Clinical decisions are driven by thyroid-stimulating hormone, free T4, and symptoms.

The reasonable retesting situations:

Monitoring response to an intervention (selenium, gluten-free, low dose naltrexone). The usual comparison is a baseline test and a second test at 6 months on the same assay/lab.
Pregnancy planning and early pregnancy — TPO status guides risk of postpartum thyroiditis and miscarriage, and often changes thyroid hormone targets.
Diagnostic uncertainty — borderline first result, ambiguous imaging, or a confusing clinical picture.

Otherwise, once you know you have Hashimoto's, annual antibody measurement is optional. Annual thyroid-stimulating hormone and free T4 are the standard.

Why Zero Isn't Always Possible or Necessary

Some patients set a goal of driving TPO into the undetectable range. For most people, this is neither achievable nor necessary. The autoimmune process, once established, tends to smolder for life at some baseline level. The clinically meaningful goals are different:

Symptom control — feel well on whatever combination of hormone replacement and lifestyle works for you.
Preserving remaining thyroid tissue — slowing progression to full gland failure, which extends the years you can live on lower doses or on no medication at all.
Reducing flare frequency — periods of higher antibody activity often correlate with fatigue, hair loss, and anxiety even when thyroid-stimulating hormone is in range.
Lowering related-disease risk — addressing the autoimmune milieu may reduce the risk of picking up a second autoimmune condition.

A stable TPO of 150 on no treatment, with normal thyroid-stimulating hormone and no symptoms, is a better outcome than a TPO of 10 achieved by an unsustainable protocol. The downstream outcomes matter more than the number.

TgAb's Special Role in Thyroid Cancer Monitoring

After surgery and radioiodine ablation for differentiated thyroid cancer, doctors follow serum thyroglobulin as a tumor marker. A rising Tg after total thyroidectomy means residual or recurrent cancer. But TgAb interferes with the thyroglobulin immunoassay: when TgAb is present, it binds Tg in the sample tube and the assay falsely reports Tg as lower than it really is. A patient with undetectable Tg but positive TgAb may actually have active disease.

This is why cancer follow-up labs always include TgAb alongside Tg, and why persistent or rising TgAb after thyroidectomy can itself be a surrogate marker of disease recurrence. For thyroid cancer survivors who also have Hashimoto's, some laboratories offer a liquid chromatography–tandem mass spectrometry (LC-MS/MS) thyroglobulin assay, which is less affected by antibody interference.

Antibody-Negative Hashimoto's

Roughly 5–10% of patients with biopsy-proven or imaging-proven Hashimoto's are antibody-negative. Their clinical picture looks like Hashimoto's — progressive hypothyroidism, a firm or heterogeneous thyroid on exam, the classic hypoechoic pseudonodular ultrasound pattern — but TPO and TgAb are both negative or borderline. Possible reasons include antibodies directed at non-measured epitopes, purely cell-mediated disease without significant antibody production, or low-titer antibodies below the assay threshold.

If symptoms, thyroid-stimulating hormone, and ultrasound all point to Hashimoto's but antibodies are negative, the diagnosis can still be made on the clinical and imaging picture. Treatment is identical. A negative antibody panel does not rule out the diagnosis when the clinical picture is strong.

What Commonly Follows a Positive Result

The sequence commonly described after a newly discovered positive TPO or TgAb:

A full thyroid panel. Thyroid-stimulating hormone, free T4, and free T3 at minimum. Reverse T3 is optional — see the reverse T3 article. A thyroid ultrasound is often done once to document baseline architecture.
A monitoring cadence. With a normal thyroid-stimulating hormone, thyroid-stimulating hormone and free T4 are commonly repeated annually — sooner if symptoms develop. With a subclinical-high thyroid-stimulating hormone, or in pregnancy or when planning pregnancy, monitoring is more frequent.
Selenium 200 mcg/day is the dose used in the trials above (selenite in Gärtner 2002, L-selenomethionine in Mazokopakis 2007), with TPO measured before and after on the same assay. The adult tolerable upper intake level is 400 mcg/day.
A strict gluten-free diet was followed for 6 months in the Krysiak pilot study. Celiac screening (tissue transglutaminase IgA antibodies, tTG-IgA, measured with total immunoglobulin A, IgA) is usually done before starting, since a gluten-free diet invalidates celiac testing.
Common deficiencies. 25-hydroxyvitamin D, ferritin, and B12 are commonly checked; targets some practitioners use are 40–60 ng/mL for vitamin D, 50–100 ng/mL for ferritin, and the upper half of the range for B12. See Selenium, Zinc, Iron, Iodine for dosing details.
Iodine megadoses are linked to rising antibodies in established Hashimoto's (see above); the Recommended Dietary Allowance is 150 mcg/day for adults and 220 mcg in pregnancy.
Stressors linked to autoimmune flares — sleep, stable blood sugar, consistent exercise, and stress regulation are described as mattering at the margins.
On conversion to overt hypothyroidism, the options are compared in levothyroxine vs natural desiccated thyroid (NDT) vs T3 and the optimal-range discussion in thyroid-stimulating hormone, T4, T3 Optimal Ranges.

The overarching message: a positive antibody result is information, not an emergency. Most people with positive TPO live decades before — or without ever — needing thyroid hormone replacement. The steps above aim to slow the process where they can and to catch the inflection point early.

Key Research Papers

Foundational and recent peer-reviewed publications on thyroid autoantibodies, their epidemiology, diagnostic significance, and the interventions studied for lowering them. Each citation links to the full text via DOI.

Caturegli P, De Remigis A, Rose NR. Hashimoto Thyroiditis: Clinical and Diagnostic Criteria. Autoimmunity Reviews. 2014;13(4-5):391–397. — doi:10.1016/j.autrev.2014.01.007
Hollowell JG, Staehling NW, Flanders WD, et al. Serum TSH, T4, and Thyroid Antibodies in the United States Population (NHANES III). Journal of Clinical Endocrinology & Metabolism. 2002;87(2):489–499. — doi:10.1210/jcem.87.2.8182
Gärtner R, Gasnier BCH, Dietrich JW, Krebs B, Angstwurm MWA. Selenium Supplementation in Patients with Autoimmune Thyroiditis Decreases Thyroid Peroxidase Antibodies Concentrations. Journal of Clinical Endocrinology & Metabolism. 2002;87(4):1687–1691. — doi:10.1210/jcem.87.4.8421
Toulis KA, Anastasilakis AD, Tzellos TG, Goulis DG, Kouvelas D. Selenium Supplementation in the Treatment of Hashimoto's Thyroiditis: A Systematic Review and a Meta-Analysis. Thyroid. 2010;20(10):1163–1173. — doi:10.1089/thy.2009.0351
Krysiak R, Szkróbka W, Okopień B. The Effect of Gluten-Free Diet on Thyroid Autoimmunity in Drug-Naïve Women with Hashimoto's Thyroiditis: A Pilot Study. Experimental and Clinical Endocrinology & Diabetes. 2019;127(7):417–422. — doi:10.1055/a-0653-7108
Sategna-Guidetti C, Volta U, Ciacci C, et al. Prevalence of Thyroid Disorders in Untreated Adult Celiac Disease Patients and Effect of Gluten Withdrawal: An Italian Multicenter Study. American Journal of Gastroenterology. 2001;96(3):751–757. — doi:10.1016/s0002-9270(00)02410-2
Nordio M, Pajalich R. Combined Treatment with Myo-Inositol and Selenium Ensures Euthyroidism in Subclinical Hypothyroidism Patients with Autoimmune Thyroiditis. Journal of Thyroid Research. 2013;2013:424163. — doi:10.1155/2013/424163
Mazokopakis EE, Papadakis JA, Papadomanolaki MG, et al. Effects of 12 Months Treatment with L-Selenomethionine on Serum Anti-TPO Levels in Patients with Hashimoto's Thyroiditis. Thyroid. 2007;17(7):609–612. — doi:10.1089/thy.2007.0040
Wichman J, Winther KH, Bonnema SJ, Hegedus L. Selenium Supplementation Significantly Reduces Thyroid Autoantibody Levels in Patients with Chronic Autoimmune Thyroiditis: A Systematic Review and Meta-Analysis. Thyroid. 2016;26(12):1681–1692. — doi:10.1089/thy.2016.0256
Vanderpump MPJ, Tunbridge WMG, French JM, et al. The Incidence of Thyroid Disorders in the Community: A Twenty-Year Follow-Up of the Whickham Survey. Clinical Endocrinology. 1995;43(1):55–68. — doi:10.1111/j.1365-2265.1995.tb01894.x
Mazokopakis EE, Papadomanolaki MG, Tsekouras KC, et al. Is Vitamin D Related to Pathogenesis and Treatment of Hashimoto's Thyroiditis? Hellenic Journal of Nuclear Medicine. 2015;18(3):222–227. — PubMed PMID: 26637501
Spencer CA, Takeuchi M, Kazarosyan M, et al. Serum Thyroglobulin Autoantibodies: Prevalence, Influence on Serum Thyroglobulin Measurement, and Prognostic Significance in Patients with Differentiated Thyroid Carcinoma. Journal of Clinical Endocrinology & Metabolism. 1998;83(4):1121–1127. — doi:10.1210/jc.83.4.1121

PubMed Topic Searches

Live PubMed queries that update as new papers are indexed.

Back to Table of Contents